Skip to main content

Advertisement

SpringerLink
Log in

Do We Still Need Liver Surgeons in the Treatment of Colorectal Liver Metastases?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey J-N, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg. 2016;263(1):146–52.

    Article  Google Scholar 

  2. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.

    Article  Google Scholar 

  3. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–46.

    Article  CAS  Google Scholar 

  4. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.

    Article  CAS  Google Scholar 

  5. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103(10):1542–7.

    Article  CAS  Google Scholar 

  6. Vega EA, Salehi O, Nicolausso D, et al. Failure to cure patients with colorectal liver metastases: the impact of the liver surgeon quantified. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10030-0.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Conrad C, Vauthey J-N, Masayuki O, et al. Individualized treatment sequencing selection contributes to optimized survival in patients with rectal cancer and synchronous liver metastases. Ann Surg Oncol. 2017;24(13):3857–64.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA

    Eduardo A. Vega MD, Richard Freeman MD & Claudius Conrad MD, PhD

Authors
  1. Eduardo A. Vega MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Freeman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudius Conrad MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudius Conrad MD, PhD.

Ethics declarations

Disclosure

Eduardo A. Vega and Richard Freeman have no disclosures to declare. Claudius Conrad is a consultant for Olympus, FujiFilm, Stryker, Integra, and Immunitas.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vega, E.A., Freeman, R. & Conrad, C. Do We Still Need Liver Surgeons in the Treatment of Colorectal Liver Metastases?. Ann Surg Oncol 28, 7707–7708 (2021). https://doi.org/10.1245/s10434-021-10139-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10139-2

Search

Navigation